A Phase 1 interventional study of Optimized neoantigen synthetic long peptide vaccine and Poly-ICLC in Pancreas Cancer, Pancreatic Cancer and Cancer of the Pancreas, sponsored by Washington University School of Medicine. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Washington University School of Medicine · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Pancreatic Neoplasms by Washington University School of Medicine — 4 open to participants now, 6 under way, none of them phase 3. Pancreatic Neoplasms · Washington University School of Medicine.
Among the 34 studies in Pancreatic Neoplasms by Washington University School of Medicine, this one is the 14th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2022, is one of 14 in phase 1, and was the 27th registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →4 of the 34 studies in Pancreatic Neoplasms by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 12
First in 2002; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 47 across 2,936 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 27 across the 32 interventional studies, 62 across the 2 observational. Of the 26 that completed or were terminated, 14 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
1 of the studies in Pancreatic Neoplasms by Washington University School of Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06648434Washington University School of MedicineMK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies in Pancreatic Neoplasms by Washington University School of Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized phase 1 clinical trial to evaluate the safety of an optimized neoantigen synthetic long peptide (SLP) vaccines in pancreatic cancer patients following neoadjuvant chemotherapy. The neoantigen SLP vaccines will incorporate prioritized neoantigens and will be co-administered with poly-ICLC. Patients will be randomized to one of two arms: Arm 1 (neoantigen vaccine following neoadjuvant chemotherapy and surgery) or Arm 2 (neoantigen vaccine following neoadjuvant chemotherapy in the window prior to surgery).
Those who are ineligible for vaccine administration including those whose disease progresses or recurs during neoadjuvant chemo or who are otherwise unable to complete surgical resection but who had a personalized neoantigen vaccine manufactured, or significant progress has been made as determined by treating physician, are permitted to receive vaccine injections on study.
Step 0 Inclusion Criteria (A patient will be eligible for evaluation and sequencing of tissue for vaccine development only if ALL of the following criteria apply:)
Adequate bone marrow and organ function as defined below:
Step 0 Exclusion Criteria (A patient will be eligible for evaluation and sequencing of tissue for vaccine development only if ALL of the following criteria apply:)
Step 1 Eligibility: At Step 1 eligibility confirmation prior to vaccination, the above criteria must be met plus:
Reimaging within 4 weeks of last dose of chemotherapy demonstrates no evidence of progressive disease. Patients who progress on mFOLFIRINOX and transition to gemcitabine + nab-paclitaxel may still be eligible for vaccine administration at discretion of PI and treating MD provided they do not show progression following completion of chemotherapy and the patient continues to be eligible for surgical resection. Patients who, in the opinion of the treating physician, require SBRT prior to surgery will receive vaccine after surgery regardless of randomization.
**Patients who progress or recur following neoadjuvant chemotherapy or who are otherwise unable to complete a surgical resection, but who still meet other Step 1 criteria, may still be eligible for vaccine administration with documented treating physician and PI approval.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* The neoantigen peptide vaccine will be manufactured during neoadjuvant chemotherapy. Institutional standard of care chemotherapy will be given. * Peptide and poly-ICLC will be administered intramuscularly on Days 1, 4, 8, 15, 22, 50, and 78 beginning approximately 1 month after surgery. Day 1 should begin approximately 1 month after surgery.
Biological: Optimized neoantigen synthetic long peptide vaccine · Biological: Poly-ICLC
* The neoantigen peptide vaccine will be manufactured during neoadjuvant chemotherapy. Institutional standard of care chemotherapy will be given. * Peptide and poly-ICLC will be administered intramuscularly on Days 1, 4, 8, 15, and 22 during the chemotherapy holiday, and Days 50 and 78 post-operatively. Optimal timing for Day 1 is 1 week after end of chemotherapy, but Day 1 may be given up to 3 weeks after end of chemotherapy.
Biological: Optimized neoantigen synthetic long peptide vaccine · Biological: Poly-ICLC
Neoantigen vaccines will be provided on a patient-specific basis
Poly-ICLC will be supplied by Oncovir, Inc.
Also known as: Hiltonol
Safety of Neoantigen SLP Vaccine as Measured by Number of Subjects Experiencing Each Type of Adverse Event
-Adverse events will be characterized according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (CTCAE).
Time frame: Through 4 weeks after completion of last vaccination (estimated to be 108 days)
Immunogenicity of Neoantigen Peptide Vaccine as Measured by the the Number of Neoantigen-specific T Cells (Only Arm 1 and Arm 2)
* Immune monitoring will occur at baseline, at time of surgery, day 1, day 15, day 22, day 50, and day 78 for Arm 1. Optional monitoring at 1 and 2 years after last vaccine administration * Immune monitoring will occur at baseline, day 1, day 15, day 22, day 50, at the time of surgery, and day 78 for Arm 2. Optional monitoring at 1 and 2 years after last vaccine administration.
Time frame: Through approximately 2 years and 78 days
Immunogenicity of Neoantigen Peptide Vaccine as Measured by the Phenotype of Neoantigen-specific T Cells (Only Arm 1 and Arm 2)
* Immune monitoring will occur at baseline, at time of surgery, day 1, day 15, day 22, day 50, and day 78 for Arm 1. Optional monitoring at 1 and 2 years after last vaccine administration * Immune monitoring will occur at baseline, day 1, day 15, day 22, day 50, at the time of surgery, and day 78 for Arm 2. Optional monitoring at 1 and 2 years after last vaccine administration.
Time frame: Through approximately 2 years and 78 days
| Milestone | Arm 1: Vaccine Given After Neoadjuvant Chemotherapy and Surgery | Arm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before Surgery |
|---|---|---|
| Started | 19 | 14 |
| Completed | 9 | 8 |
| Not completed | 10 | 6 |
| Withdrew: Did not start treatment - biopsy did not provide sufficient rna yield | 5 | 3 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Did not start treatment - tumor cellularity extremely low | 1 | 0 |
| Withdrew: Did not start treatment - participant withdrawal | 1 | 1 |
| Withdrew: Did not start treatment - disease progression | 1 | 1 |
| Withdrew: Did not start treatment - physician decision | 1 | 0 |
-Adverse events will be characterized according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (CTCAE).
| Participants | Arm 1: Vaccine Given After Neoadjuvant Chemotherapy and Surgery | Arm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before Surgery |
|---|---|---|
| Grade 1/2 anemia | 2 | 4 |
| Grade 3/4/5 anemia | 1 | 2 |
| Grade 1/2 eosinophilia | 0 | 1 |
| Grade 3/4/5 myocardial infarction | 1 | 0 |
| Grade 1/2 double vision | 1 | 0 |
| Grade 1/2 abdominal cramping | 0 | 1 |
| Grade 1/2 abdominal pain | 2 | 3 |
| Grade 1/2 colitis | 1 | 0 |
| Grade 1/2 constipation | 1 | 0 |
| Grade 1/2 diarrhea | 2 | 1 |
| Grade 1/2 dyspepsia | 1 | 0 |
| Grade 1/2 gastroparesis | 0 | 1 |
| Grade 1/2 mouth sore | 0 | 1 |
| Grade 1/2 mucositis oral | 3 | 0 |
| Grade 1/2 nausea | 4 | 5 |
| Grade 1/2 vomiting | 4 | 4 |
| Grade 1/2 arm pain | 0 | 1 |
| Grade 1/2 body aches | 0 | 1 |
| Grade 1/2 chills | 4 | 4 |
| Grade 1/2 edema limbs | 1 | 2 |
| Grade 1/2 fatigue | 5 | 6 |
| Grade 1/2 fever | 4 | 3 |
| Grade 1/2 flu like symptoms | 1 | 2 |
| Grade 1/2 injection site pain in arms and legs | 0 | 1 |
| Grade 1/2 injection site reaction | 8 | 5 |
| Grade 1/2 sore arm | 0 | 1 |
| Grade 1/2 bacteremia | 0 | 1 |
| Grade 1/2 COVID-19 | 1 | 0 |
| Grade 1/2 gum infection | 1 | 1 |
| Grade 1/2 herpes simplex reactivation | 0 | 1 |
| Grade 1/2 urinary tract infection | 0 | 1 |
| Grade 1/2 alanine aminotransferase increased | 2 | 4 |
| Grade 3/4/5 alanine aminotransferase increased | 0 | 1 |
| Grade 1/2 alkaline phosphatase increased | 2 | 3 |
| Grade 3/4/5 alkaline phosphatase increased | 0 | 1 |
| Grade 1/2 aspartate aminotransferase increased | 2 | 6 |
| Grade 3/4/5 aspartate aminotransferase increased | 1 | 0 |
| Grade 1/2 blood bilirubin increased | 0 | 1 |
| Grade 1/2 blood lactate dehydrogenase increased | 1 | 0 |
| Grade 1/2 creatinine increased | 1 | 0 |
| Grade 3/4/5 creatinine increased | 0 | 1 |
| Grade 1/2 INR increased | 0 | 1 |
| Grade 1/2 lymphocyte count decreased | 1 | 2 |
| Grade 1/2 neutrophil count decreased | 1 | 1 |
| Grade 3/4/5 neutrophil count decreased | 1 | 0 |
| Grade 1/2 platelet count decreased | 1 | 1 |
| Grade 3/4/5 platelet count decreased | 0 | 1 |
| Grade 1/2 thyroid stimulating hormone increased | 1 | 0 |
| Grade 1/2 weight loss | 1 | 2 |
| Grade 1/2 white blood cell decreased | 3 | 2 |
| Grade 1/2 anorexia | 3 | 1 |
| Grade 3/4/5 anorexia | 0 | 1 |
| Grade 1/2 hyperglycemia | 3 | 6 |
| Grade 1/2 hypermagnesemia | 0 | 1 |
| Grade 1/2 hypernatremia | 0 | 1 |
| Grade 1/2 hyperphosphatemia | 0 | 3 |
| Grade 1/2 hypoalbuminemia | 2 | 2 |
| Grade 3/4/5 hypoalbuminemia | 0 | 1 |
| Grade 1/2 hypocalcemia | 2 | 3 |
| Grade 1/2 hypoglycemia | 0 | 1 |
| Grade 1/2 hypokalemia | 2 | 2 |
| Grade 3/4/5 hypokalemia | 0 | 1 |
| Grade 1/2 hyponatremia | 1 | 2 |
| Grade 1/2 hypophosphatemia | 0 | 2 |
| Grade 1/2 arthralgia | 3 | 0 |
| Grade 1/2 buttock pain | 0 | 1 |
| Grade 1/2 generalized muscle weakness | 1 | 0 |
| Grade 3/4/5 generalized muscle weakness | 0 | 1 |
| Grade 1/2 myalgia | 3 | 0 |
| Grade 1/2 dizziness | 2 | 1 |
| Grade 1/2 dysgeusia | 1 | 1 |
| Grade 1/2 headache | 0 | 4 |
| Grade 3/4/5 headache | 0 | 1 |
| Grade 3/4/5 intracranial hemorrhage | 0 | 1 |
| Grade 1/2 peripheral sensory neuropathy | 2 | 2 |
| Grade 1/2 tremor | 1 | 0 |
| Grade 1/2 anxiety | 0 | 1 |
| Grade 1/2 depression | 1 | 1 |
| Grade 3/4/5 chronic kidney disease | 0 | 1 |
| Grade 1/2 urinary frequency | 0 | 1 |
| Grade 1/2 dyspnea | 1 | 2 |
| Grade 1/2 sore throat | 1 | 0 |
| Grade 1/2 alopecia | 0 | 1 |
| Grade 1/2 dry lips | 1 | 0 |
| Grade 1/2 dry skin | 1 | 0 |
| Grade 1/2 hyperhidrosis | 1 | 0 |
| Grade 1/2 itching on face | 0 | 1 |
| Grade 1/2 rash maculo-papular | 0 | 1 |
| Grade 1/2 skin hyperpigmentation | 1 | 0 |
| Grade 1/2 hypertension | 1 | 1 |
| Grade 3/4/5 hypertension | 0 | 1 |
| Grade 1/2 hypotension | 1 | 0 |
| Grade 3/4/5 thromboembolic event | 0 | 1 |
* Immune monitoring will occur at baseline, at time of surgery, day 1, day 15, day 22, day 50, and day 78 for Arm 1. Optional monitoring at 1 and 2 years after last vaccine administration * Immune monitoring will occur at baseline, day 1, day 15, day 22, day 50, at the time of surgery, and day 78 for Arm 2. Optional monitoring at 1 and 2 years after last vaccine administration.
Results for this outcome have not been posted.
* Immune monitoring will occur at baseline, at time of surgery, day 1, day 15, day 22, day 50, and day 78 for Arm 1. Optional monitoring at 1 and 2 years after last vaccine administration * Immune monitoring will occur at baseline, day 1, day 15, day 22, day 50, at the time of surgery, and day 78 for Arm 2. Optional monitoring at 1 and 2 years after last vaccine administration.
Results for this outcome have not been posted.
Collected over Adverse events were collected from first dose of vaccine through 4 weeks after the last vaccination (up to 78 days and 4 weeks). All-cause mortality is collected from first dose of vaccine through completion of follow-up (up to 2 years and 78 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: Vaccine Given After Neoadjuvant Chemotherapy and Surgery | 4/10 (40%) | 1/10 (10%) | 10/10 (100%) |
| Arm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before Surgery | 3/9 (33.3%) | 4/9 (44.4%) | 9/9 (100%) |
| Event | Arm 1: Vaccine Given After Neoadjuvant Chemotherapy and Surgery | Arm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before Surgery |
|---|---|---|
| GastroparesisGastrointestinal disorders | 0/10 | 1/9 |
| BacteremiaInfections and infestations | 0/10 | 1/9 |
| Generalized muscle weaknessMusculoskeletal and connective tissue disorders | 0/10 | 1/9 |
| HeadacheNervous system disorders | 0/10 | 1/9 |
| Intracranial hemorrhageNervous system disorders | 0/10 | 1/9 |
| HypertensionVascular disorders | 0/10 | 1/9 |
| Thromboembolic eventVascular disorders | 0/10 | 1/9 |
| Myocardial infarctionCardiac disorders | 1/10 | 0/9 |
| Event | Arm 1: Vaccine Given After Neoadjuvant Chemotherapy and Surgery | Arm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before Surgery |
|---|---|---|
| Injection site reactionGeneral disorders | 8/10 | 5/9 |
| AnemiaBlood and lymphatic system disorders | 3/10 | 6/9 |
| FatigueGeneral disorders | 5/10 | 6/9 |
| Aspartate aminotransferase increasedInvestigations | 3/10 | 6/9 |
| HyperglycemiaMetabolism and nutrition disorders | 3/10 | 6/9 |
| NauseaGastrointestinal disorders | 4/10 | 5/9 |
| Alanine aminotransferase increasedInvestigations | 2/10 | 5/9 |
| VomitingGastrointestinal disorders | 4/10 | 4/9 |
| ChillsGeneral disorders | 4/10 | 4/9 |
| Alkaline phosphatase increasedInvestigations | 2/10 | 4/9 |
| Age, Continuous(years) | Arm 1: Vaccine Given After Neoadjuvant Chemotherapy and Surgery | Arm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before Surgery | Total |
|---|---|---|---|
| Median | 69 (56 to 81) | 65.5 (47 to 80) | 68 (47 to 81) |
| Sex: Female, Male(Participants) | Arm 1: Vaccine Given After Neoadjuvant Chemotherapy and Surgery | Arm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before Surgery | Total |
|---|---|---|---|
| Female | 12 | 3 | 15 |
| Male | 7 | 11 | 18 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1: Vaccine Given After Neoadjuvant Chemotherapy and Surgery | Arm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before Surgery | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 |
| Not Hispanic or Latino | 17 | 14 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arm 1: Vaccine Given After Neoadjuvant Chemotherapy and Surgery | Arm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before Surgery | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 16 | 14 | 30 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Arm 1: Vaccine Given After Neoadjuvant Chemotherapy and Surgery | Arm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before Surgery | Total |
|---|---|---|---|
| United States | 19 | 14 | 33 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Sequencing data will be submitted to the database of Genotypes and Phenotypes (dbGap) at the National Cancer Institute.
Ran from Dec 2022 to primary completion in Nov 2025, 34 months.
Results were first posted in Nov 2026, 1 year after primary completion.
Of 209 non-industry phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 74. This study's 34 months is below that.
Counting every sponsor, half of 380 studies reached it within 45 months; a quarter within 32 and three quarters within 68.
Completion moved once since we started tracking on Sep 25, 2026: Nov 2025 → Oct 2027, on Nov 3, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Poly ICLC
Washington University School of Medicine →